A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer

High-grade serous ovarian cancer, the most frequent type of ovarian cancer, has a poor prognosis and novel treatments are needed for patients with platinum resistant/refractory disease. New therapeutic strategies targeting cell cycle checkpoints, including CHK1 inhibition with prexasertib, may help...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology 2022-11, Vol.167 (2), p.213-225
Hauptverfasser: Konstantinopoulos, Panagiotis A., Lee, Jung-min, Gao, Bo, Miller, Rowan, Lee, Jung-Yun, Colombo, Nicoletta, Vergote, Ignace, Credille, Kelly M., Young, Suzanne R., McNeely, Samuel, Wang, Xuejing Aimee, Lin, Aimee Bence, Shapira-Frommer, Ronnie
Format: Artikel
Sprache:eng
Schlagworte:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Carcinoma, Ovarian Epithelial - drug therapy
Checkpoint kinase inhibitor
Female
Humans
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - pathology
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
Platinum - therapeutic use
Platinum refractory
Platinum resistant
Poly(ADP-ribose) Polymerase Inhibitors - adverse effects
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:High-grade serous ovarian cancer, the most frequent type of ovarian cancer, has a poor prognosis and novel treatments are needed for patients with platinum resistant/refractory disease. New therapeutic strategies targeting cell cycle checkpoints, including CHK1 inhibition with prexasertib, may help improve clinical response and overcome resistance. Patients with ovarian cancer (N = 169) were assigned to 4 cohorts as part of the Phase 2 multicenter trial (NCT03414047): Cohort 1: platinum resistant, BRCA-wildtype with ≥3 lines prior therapy; Cohort 2: platinum resistant BRCA-wildtype with
ISSN:0090-8258
1095-6859
1095-6859
DOI:10.1016/j.ygyno.2022.09.019